Merus N.V. (MRUS): Price and Financial Metrics


Merus N.V. (MRUS): $22.00

-0.30 (-1.35%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add MRUS to Watchlist
Sign Up

Industry: Biotech


Ranked

of 493

in industry

MRUS POWR Grades


  • MRUS scores best on the Value dimension, with a Value rank ahead of 72.17% of US stocks.
  • MRUS's strongest trending metric is Value; it's been moving down over the last 206 days.
  • MRUS's current lowest rank is in the Momentum metric (where it is better than 11.51% of US stocks).

MRUS Stock Summary

  • For MRUS, its debt to operating expenses ratio is greater than that reported by merely 7.21% of US equities we're observing.
  • MRUS's price/sales ratio is 26.37; that's higher than the P/S ratio of 92.37% of US stocks.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for MRUS comes in at -22.45% -- higher than that of only 12.1% of stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Merus NV are MTEM, DTIL, SGMO, CDXS, and CERC.
  • Visit MRUS's SEC page to see the company's official filings. To visit the company's web site, go to www.merus.nl.

MRUS Price Target

For more insight on analysts targets of MRUS, see our MRUS price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $27.75 Average Broker Recommendation 1.33 (Strong Buy)

MRUS Stock Price Chart Interactive Chart >

Price chart for MRUS

MRUS Price/Volume Stats

Current price $22.00 52-week high $31.27
Prev. close $22.30 52-week low $10.18
Day low $20.41 Volume 116,000
Day high $23.02 Avg. volume 153,769
50-day MA $22.22 Dividend yield N/A
200-day MA $17.89 Market Cap 843.70M

Merus N.V. (MRUS) Company Bio


Merus B.V., a clinical-stage immuno-oncology company, engages in developing bispecific antibody therapeutics. The company was founded in 2003 and is based in Utrecht, Netherlands.


MRUS Latest News Stream


Event/Time News Detail
Loading, please wait...

MRUS Latest Social Stream


Loading social stream, please wait...

View Full MRUS Social Stream

Latest MRUS News From Around the Web

Below are the latest news stories about Merus NV that investors may wish to consider to help them evaluate MRUS as an investment opportunity.

Merus to Participate in a Fireside Chat at the 2021 RBC Capital Markets Global Healthcare Conference

UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 11, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Bill Lundberg, M.D., Chief Executive Officer of Merus, will participate in a fireside chat at the 2021 RBC Capital Markets Global Healthcare Conference on Tuesday, May 18 at 8:00 a.m. ET. The live webcast of the presentation will be available on the Investors page of the Company's website. An archived presentation will be available on the Merus website for a limited time. About MerusMerus is a clinical-stage oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonic...

Yahoo | May 11, 2021

Merus N.V. (MRUS) Reports Q1 Loss, Lags Revenue Estimates

Merus N.V. (MRUS) delivered earnings and revenue surprises of -27.27% and -63.08%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | May 6, 2021

Merus Announces Financial Results for the First Quarter and Provides Business Update

Clinical data update on zenocutuzumab selected for oral presentation at ASCO MCLA-145 clinical update planned for 2H21 MCLA-129 first patient dosed in phase 1/2 trial Cecile Geuijen, Ph.D., promoted to Chief Scientific Officer UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 06, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company,” “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced financial results for the first quarter that ended March 31, 2021, and provided a business update. “We have made significant progress on our clinical programs this quarter and we are excited to provide a clinical data update on Zeno in an oral presentation at ASCO in June, and on M...

Yahoo | May 6, 2021

Merus Announces First Patient Treated in Phase 1/2 Clinical Trial of MCLA-129 in Advanced Lung Cancer and Other Solid Tumors

Merus’ Fourth Sponsored Bispecific Antibody Currently in Clinical TrialsUTRECHT, The Netherlands and CAMBRIDGE, Mass., May 03, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that the first patient has been treated in its phase 1/2 dose escalation and expansion trial evaluating MCLA-129 for the treatment of patients with advanced non-small cell lung cancer (NSCLC) and other solid tumors. MCLA-129 is a Biclonics®, which binds to EGFR and c-MET. EGFR is an important oncogenic driver in many cancers, and upregulation of c-MET signaling has been associated with resistance to EGFR inhibition. “The initiation o...

Yahoo | May 3, 2021

Merus Announces Poster Presentations for Zenocutuzumab and MCLA-129 at the American Association for Cancer Research 2021 Annual Meeting

UTRECHT, The Netherlands and CAMBRIDGE, Mass., March 10, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Merus will present preclinical data from our zenocutuzumab and MCLA-129 programs in three poster presentations at the American Association for Cancer Research 2021 Annual Meeting being held virtually for two weeks, April 10-15, 2021 and May 17-21, 2021. E-Poster Presentation: Title: The HER2×HER3 bi-specific antibody zenocutuzumab is effective at blocking growth of tumors driven by NRG1 gene fusionsAbstract #: 956Session Category: Experimental and Molecular TherapeuticsSession Title: Biological Th...

Yahoo | March 10, 2021

Read More 'MRUS' Stories Here

MRUS Price Returns

1-mo -5.25%
3-mo -11.65%
6-mo 67.43%
1-year 54.39%
3-year 29.41%
5-year N/A
YTD 25.50%
2020 24.50%
2019 0.57%
2018 -27.84%
2017 -8.10%
2016 N/A

Continue Researching MRUS

Want to see what other sources are saying about Merus NV's financials and stock price? Try the links below:

Merus NV (MRUS) Stock Price | Nasdaq
Merus NV (MRUS) Stock Quote, History and News - Yahoo Finance
Merus NV (MRUS) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.9805 seconds.